Reassessing the Net Benefit of Cancer Drugs With Evolution of Evidence Using the ASCO Value Framework

CONCLUSIONS: Because there were changes in classification for more than one-quarter of indications, in either direction, reassessing the ASCO-VF NHB as more evidence becomes available may be beneficial to inform clinical shared decision-making. On average, there was no overall improvement in the ASCO-VF NHB with longer follow-up and evolution of evidence.PMID:33636693 | DOI:10.6004/jnccn.2020.7677
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Authors: Source Type: research